
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Teriflunomide
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Breckenridge Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Teriflunomide – API and Licensing Agreements for Tablets Available
Details : The received FDA approval will allow Breckenridge, to launch generic Teriflunomide in the US market from the beginning of 2023 onwards. Teriflunomide, a small molecule is a generic of Aubagio® available in 7mg & 14mg Tablets.
Product Name : Teriflunomide-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 06, 2021
Lead Product(s) : Teriflunomide
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Breckenridge Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable


